Carnitine palmitoyltransferase I
|Carnitine palmitoyltransferase 1A (liver)|
|Symbols||; CPT1; CPT1-L; L-CPT1|
Carnitine palmitoyltransferase I (CPT1) also known as carnitine acyltransferase I, CPTI, CAT1, CoA:carnitine acyl transferase (CCAT), or palmitoylCoA transferase I, is a mitochondrial enzyme responsible for the formation of acyl carnitines by catalyzing the transfer of the acyl group of a long-chain fatty acyl-CoA from coenzyme A to l-carnitine. The product is often Palmitoylcarnitine (thus the name), but other fatty acids may also be substrates. It is part of a family of enzymes called carnitine acyltransferases. This "preparation" allows for subsequent movement of the acyl carnitine from the cytosol into the intermembrane space of mitochondria.
Three isoforms of CPT1 are currently known: CPT1A, CPT1B, and CPT1C. CPT1 is associated with the outer mitochondrial membrane. This enzyme can be inhibited by malonyl CoA, the first committed intermediate produced during fatty acid synthesis. Its role in fatty acid metabolism makes CPT1 important in many metabolic disorders such as diabetes. Since its crystal structure is not known, its exact mechanism of action remains to be determined.
CPT1 is an integral membrane protein that associates with the mitochondrial outer membrane through transmembrane regions in the peptide chain. Both the N- and C-terminal domains are exposed to the cytosolic side of the membrane.
Three isoforms of CPT1 exist in mammalian tissues. The liver isoform (CPT1A or CPTI-L) is found throughout the body on the mitochondria of all cells except for skeletal muscle cells and brown adipose cells. The muscle isoform (CPT1B or CPTI-M) is highly expressed in heart and skeletal muscle cells and brown adipose cells. A third isoform, the brain isoform (CPT1C), was isolated in 2002. It is expressed predominantly in the brain and testes. Little is known about CPT1C.
The exact structure of any of the CPT1 isoforms has not yet been determined, although a variety of in silico models for CPT1 have been created based on closely related carnitine acyltransferases, such as carnitine acetyltransferase (CRAT).
An important structural difference between CPT1 and CPT2, CRAT and carnitine octanoyltransferase (COT) is that CPT1 contains an additional domain at its N-terminal consisting of about 160 amino acids. It has been determined that this additional N-terminal domain is important for the key inhibitory molecule of CPT1, malonyl-CoA.
Two distinct binding sites have been proposed to exist in CPT1A and CPT1B. The “A site” or “CoA site” appears to bind both malonyl-CoA and palmitoyl-CoA, as well as other molecules containing coenzyme A, suggesting that the enzyme binds these molecules via interaction with the coenzyme A moiety. It has been suggested that malonyl-CoA may behave as a competitive inhibitor of CPT1A at this site. A second “O site” has been proposed to bind malonyl-CoA more tightly than the A site. Unlike the A site, the O site binds to malonyl-CoA via the dicarbonyl group of the malonate moiety of malonyl-CoA. The binding of malonyl-CoA to either the A and O sites inhibits the action of CPT1A by excluding the binding of carnitine to CPT1A. Since a crystal structure of CTP1A has yet to be isolated and imaged, its exact structure remains to be elucidated.
Because crystal structure data is currently unavailable, the exact mechanism of CPT1 is not currently known. A couple different possible mechanisms for CPT1 have been postulated, both of which include the histidine residue 473 as the key catalytic residue. One such mechanism based upon a carnitine acetyltransferase model is shown below in which the His 473 deprotonates carnitine while a nearby serine residue stabilizes the tetrahedral oxyanion intermediate.
A different mechanism has been proposed that suggests that a catalytic triad composed of residues Cys-305, His-473, and Asp-454 carries out the acyl-transferring step of catalysis. This catalytic mechanism involves the formation of a thioacyl-enzyme covalent intermediate with Cys-305.
The carnitine palmitoyltransferase system is an essential step in the beta-oxidation of long chain fatty acids. This transfer system is necessary because, while fatty acids are activated (in the form of a thioester linkage to coenzyme A) on the outer mitochondrial membrane, the activated fatty acids must be oxidized within the mitochondrial matrix. Long chain fatty acids such as palmitoyl-CoA, unlike short- and medium-chain fatty acids, cannot freely diffuse through the mitochondrial inner membrane, and require a shuttle system to be transported to the mitochondrial matrix.
Carnitine palmitoyltransferase I is the first component and rate-limiting step of the carnitine palmitoyltransferase system, catalyzing the transfer of the acyl group from coenzyme A to carnitine to form palmitoylcarnitine. A translocase then shuttles the acyl carnitine across the inner mitochondrial membrane where it is converted back into palmitoyl-CoA.
By acting as an acyl group acceptor, carnitine may also play the role of regulating the intracellular CoA:acyl-CoA ratio.
CPT1 is inhibited by malonyl-CoA, although the exact mechanism of inhibition remains unknown. The CPT1 skeletal muscle and heart isoform, CPT1B, has been shown to be 30-100-fold more sensitive to malonyl-CoA inhibition than CPT1A. This inhibition is a good target for future attempts to regulate CPT1 for the treatment of metabolic disorders.
Acetyl-CoA carboxylase (ACC), the enzyme that catalyzes the formation of malonyl-CoA from acetyl-CoA, is important in the regulation of fatty acid metabolism. Scientists have demonstrated that ACC2 knockout mice have reduced body fat and weight when compared to wild type mice. This is a result of decreased activity of ACC which causes a subsequent decrease in malonyl-CoA concentrations. These decreased malonyl-CoA levels in turn prevent inhibition of CPT1, causing an ultimate increase in fatty acid oxidation. Since heart and skeletal muscle cells have a low capacity for fatty acid synthesis, ACC may act purely as a regulatory enzyme in these cells.
The "CPT1A" form is associated with carnitine palmitoyltransferase I deficiency. This rare disorder confers risk for hepatic encephalopathy, hypoketotic hypoglycemia, seizures, and sudden unexpected death in infancy.
CPT1 is associated with type 2 diabetes and insulin resistance. Such diseases, along with many other health problems, cause free fatty acid (FFA) levels in humans to become elevated, fat to accumulate in skeletal muscle, and decreases the ability of muscles to oxidize fatty acids. CPT1 has been implicated in contributing to these symptoms. The increased levels of malonyl-CoA caused by hyperglycemia and hyperinsulinemia inhibit CPT1, which causes a subsequent decrease in the transport of long chain fatty acids into muscle and heart mitochondria, decreasing fatty acid oxidation in such cells. The shunting of LCFAs away from mitochondria leads to the observed increase in FFA levels and the accumulation of fat in skeletal muscle.
New research presented at the 2015 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) suggests that CPT1 may also play a role in the pathology of multiple sclerosis (MS). Researchers have found that mutations in the CPT1 gene appear to protect against MS in certain populations. The hypothesis is that increased lipid metabolism may help drive myelin destruction, and allowing an autoimmune attack on the nerve cells. John Dirk Nieland, PhD, and colleagues from Aalborg University in Denmark presented data showing that in animal models of MS, blocking CPT1 with a molecule called etomoxir appears to ameliorate the symptoms of MS. the researchers are now seeking support for a clinical trial in human patients.
Its importance in fatty acid metabolism makes CPT1 a potentially useful enzyme to focus on in the development of treatments of many other metabolic disorders as well.
CPT1 is known to interact with many proteins, including ones from the NDUF family, PKC1, and ENO1.
In HIV, Vpr enhances PPARbeta/delta-induced PDK4, carnitine palmitoyltransferase I (CPT1) mRNA expression in cells. Knockdown of CPT1A by shRNA library screening inhibits HIV-1 replication in cultured Jurkat T-cells.
- van der Leij FR, Huijkman NC, Boomsma C, Kuipers JR, Bartelds B (2000). "Genomics of the human carnitine acyltransferase genes". Molecular Genetics and Metabolism 71 (1-2): 139–53. doi:10.1006/mgme.2000.3055. PMID 11001805.
- Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J (2004). "Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects". Molecular Aspects of Medicine 25 (5-6): 495–520. doi:10.1016/j.mam.2004.06.004. PMID 15363638.
- Jogl G, Tong L (Jan 2003). "Crystal structure of carnitine acetyltransferase and implications for the catalytic mechanism and fatty acid transport". Cell 112 (1): 113–22. doi:10.1016/S0092-8674(02)01228-X. PMID 12526798.
- Yamazaki N, Yamanaka Y, Hashimoto Y, Shinohara Y, Shima A, Terada H (Jun 1997). "Structural features of the gene encoding human muscle type carnitine palmitoyltransferase I". FEBS Letters 409 (3): 401–406. doi:10.1016/S0014-5793(97)00561-9. PMID 9224698.
- Brown NF, Hill JK, Esser V, Kirkland JL, Corkey BE, Foster DW, McGarry JD (Oct 1997). "Mouse white adipocytes and 3T3-L1 cells display an anomalous pattern of carnitine palmitoyltransferase (CPT) I isoform expression during differentiation. Inter-tissue and inter-species expression of CPT I and CPT II enzymes". The Biochemical Journal. 327 ( Pt 1): 225–31. PMC 1218784. PMID 9355756.
- Lee J, Ellis JM, Wolfgang MJ (Jan 2015). "Adipose fatty acid oxidation is required for thermogenesis and potentiates oxidative stress-induced inflammation". Cell Reports 10 (2): 266–279. doi:10.1016/j.celrep.2014.12.023. PMID 25578732.
- Price N, van der Leij F, Jackson V, Corstorphine C, Thomson R, Sorensen A, Zammit V (Oct 2002). "A novel brain-expressed protein related to carnitine palmitoyltransferase I". Genomics 80 (4): 433–442. doi:10.1006/geno.2002.6845. PMID 12376098.
- Lavrentyev EN, Matta SG, Cook GA (Feb 2004). "Expression of three carnitine palmitoyltransferase-I isoforms in 10 regions of the rat brain during feeding, fasting, and diabetes". Biochemical and Biophysical Research Communications 315 (1): 174–178. doi:10.1016/j.bbrc.2004.01.040. PMID 15013442.
- Morillas M, López-Viñas E, Valencia A, Serra D, Gómez-Puertas P, Hegardt FG, Asins G (May 2004). "Structural model of carnitine palmitoyltransferase I based on the carnitine acetyltransferase crystal". The Biochemical Journal 379 (Pt 3): 777–784. doi:10.1042/BJ20031373. PMC 1224103. PMID 14711372.
- Woldegiorgis G, Dai J, Arvidson D (2005). "Structure-Function Studies with the Mitochondrial Carnitine Palmitoyltransferases I and II". Monatshefte fur Chemie 136 (8): 1325–1340. doi:10.1007/s00706-005-0334-7.
- López-Viñas E, Bentebibel A, Gurunathan C, Morillas M, de Arriaga D, Serra D, Asins G, Hegardt FG, Gómez-Puertas P (Jun 2007). "Definition by functional and structural analysis of two malonyl-CoA sites in carnitine palmitoyltransferase 1A". The Journal of Biological Chemistry 282 (25): 18212–24. doi:10.1074/jbc.M700885200. PMID 17452323.
- Liu H, Zheng G, Treber M, Dai J, Woldegiorgis G (Feb 2005). "Cysteine-scanning mutagenesis of muscle carnitine palmitoyltransferase I reveals a single cysteine residue (Cys-305) is important for catalysis". The Journal of Biological Chemistry 280 (6): 4524–4531. doi:10.1074/jbc.M400893200. PMID 15579906.
- Berg JM, Tymoczo JL, Stryer L, "Biochemistry", 6th edition 2007
- Jogl G, Hsiao YS, Tong L (Nov 2004). "Structure and function of carnitine acyltransferases". Annals of the New York Academy of Sciences 1033 (1): 17–29. doi:10.1196/annals.1320.002. PMID 15591000.
- Shi J, Zhu H, Arvidson DN, Woldegiorgis G (Feb 2000). "The first 28 N-terminal amino acid residues of human heart muscle carnitine palmitoyltransferase I are essential for malonyl CoA sensitivity and high-affinity binding". Biochemistry 39 (4): 712–717. doi:10.1021/bi9918700. PMID 10651636.
- Abu-Elheiga L, Oh W, Kordari P, Wakil SJ (Sep 2003). "Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets". Proceedings of the National Academy of Sciences of the United States of America 100 (18): 10207–10212. doi:10.1073/pnas.1733877100. PMC 193540. PMID 12920182.
- Ogawa E, Kanazawa M, Yamamoto S, Ohtsuka S, Ogawa A, Ohtake A, Takayanagi M, Kohno Y (2002). "Expression analysis of two mutations in carnitine palmitoyltransferase IA deficiency". Journal of Human Genetics 47 (7): 342–7. doi:10.1007/s100380200047. PMID 12111367.
- Collins SA, Sinclair G, McIntosh S, Bamforth F, Thompson R, Sobol I, Osborne G, Corriveau A, Santos M, Hanley B, Greenberg CR, Vallance H, Arbour L (2010). "Carnitine palmitoyltransferase 1A (CPT1A) P479L prevalence in live newborns in Yukon, Northwest Territories, and Nunavut". Molecular Genetics and Metabolism 101 (2-3): 200–204. doi:10.1016/j.ymgme.2010.07.013. PMID 20696606.
- Rasmussen BB, Holmbäck UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR (Dec 2002). "Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle". The Journal of Clinical Investigation 110 (11): 1687–93. doi:10.1172/JCI15715. PMC 151631. PMID 12464674.
- McGarry JD, Mills SE, Long CS, Foster DW (Jul 1983). "Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat". The Biochemical Journal 214 (1): 21–8. PMC 1152205. PMID 6615466.
- Wilner, AN (December 1, 2015), Exploring a New Mechanism of action for MS Drugs, An Expert Interview With John Dirk Nieland, PhD, Medscape, retrieved 3 December 2015
- Nieland, JD; Nieland, JG; Mørkholt, AS; Bolther, L; Nielsen, S (October 7–10, 2015), "Abstract P1497. CPT1a mutation leads the way for new medication for the treatment of multiple sclerosis", 31st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), Barcelona, Spain, Final Programme
- Havugimana PC, Hart GT, Nepusz T, Yang H, Turinsky AL, Li Z, Wang PI, Boutz DR, Fong V, Phanse S, Babu M, Craig SA, Hu P, Wan C, Vlasblom J, Dar VU, Bezginov A, Clark GW, Wu GC, Wodak SJ, Tillier ER, Paccanaro A, Marcotte EM, Emili A (Aug 2012). "A census of human soluble protein complexes". Cell 150 (5): 1068–81. doi:10.1016/j.cell.2012.08.011. PMID 22939629.
- Shrivastav S, Zhang L, Okamoto K, Lee H, Lagranha C, Abe Y, Balasubramanyam A, Lopaschuk GD, Kino T, Kopp JB (Sep 2013). "HIV-1 Vpr enhances PPARβ/δ-mediated transcription, increases PDK4 expression, and reduces PDC activity". Molecular Endocrinology 27 (9): 1564–76. doi:10.1210/me.2012-1370. PMID 23842279.
- Yeung ML, Houzet L, Yedavalli VS, Jeang KT (Jul 2009). "A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication". The Journal of Biological Chemistry 284 (29): 19463–73. doi:10.1074/jbc.M109.010033. PMID 19460752.